ALNYLAM Pharmaceuticals Analysis: ALNYLAM PHARMACEUTICALS, INC. (ALNY) has received a high rating of 94% from Validea's Twin Momentum Investor model, indicating strong interest based on its fundamental and price momentum within the Biotechnology & Drugs industry.
Dashan Huang's Strategy: The strategy, developed by Dashan Huang, combines traditional price momentum with improving fundamentals, identifying key variables that lead to market outperformance, particularly highlighting the effectiveness of stocks in the top 20% of his fundamental measure.
ALNY
$394.375+Infinity%1D
Analyst Views on ALNY
Wall Street analysts forecast ALNY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALNY is 497.68 USD with a low forecast of 370.00 USD and a high forecast of 570.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
21 Analyst Rating
Wall Street analysts forecast ALNY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALNY is 497.68 USD with a low forecast of 370.00 USD and a high forecast of 570.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
17 Buy
4 Hold
0 Sell
Strong Buy
Current: 397.550
Low
370.00
Averages
497.68
High
570.00
Current: 397.550
Low
370.00
Averages
497.68
High
570.00
Stifel
NULL
to
Buy
maintain
$495 -> $508
2025-12-11
New
Reason
Stifel
Price Target
$495 -> $508
2025-12-11
New
maintain
NULL
to
Buy
Reason
Stifel raised the firm's price target on Alnylam to $508 from $495 and keeps a Buy rating on the shares. The firm "refreshed diligence" on many companies within its biotechnology coverage universe and made a number of model, estimate and price target changes in a 2026 look ahead note for the group.
Wells Fargo
Tiago Fauth
Equal Weight
maintain
$395 -> $479
2025-11-11
Reason
Wells Fargo
Tiago Fauth
Price Target
$395 -> $479
2025-11-11
maintain
Equal Weight
Reason
Wells Fargo analyst Tiago Fauth raised the firm's price target on Alnylam to $479 from $395 and keeps an Equal Weight rating on the shares. The firm believes it may be hard for Alnylam to outperform in 2026. Wells sees a more balanced risk/reward, as Amvuttra estimates seem priced in at these levels. Competition and pricing narratives could also weigh on the stock, keeping it range bound, the firm adds.
Goldman Sachs
downgrade
2025-11-03
Reason
Goldman Sachs
Price Target
2025-11-03
downgrade
Reason
Goldman Sachs analysts removed Alnylam from the firm's US Conviction List as part of its monthly update.
Oppenheimer
Oppenheimer
maintain
$490 -> $500
2025-10-31
Reason
Oppenheimer
Oppenheimer
Price Target
$490 -> $500
2025-10-31
maintain
Reason
Oppenheimer raised the firm's price target on Alnylam to $500 from $490 and keeps an Outperform rating on the shares. The firm notes Amvuttra global revenue of $685M came just shy of its $690M but well ahead of the Street's $622M, and Alnylam raised full-year TTR franchise guidance by $275M at midpoint.
About ALNY
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
